Showing results (171-180 of 186) with videos related to

Sort By:
Pageof 19
Cell Death and Differentiation|April 21, 2021
CCL2 regulation of MST1-mTOR-STAT1 signaling axis controls BCR signaling and B-cell differentiationLu Yang, Na Li, Di Yang, et al.
Experimental Hematology & Oncology|October 1, 2025
Phase II study of zevorcabtagene autoleucel, a fully human BCMA-targeting CAR T cell therapy, in patients with relapsed/refractory multiple myelomaWenming Chen, Chengcheng Fu, Baijun Fang, et al.
Annals of Hematology|June 6, 2024
Switching from eltrombopag to hetrombopag in patients with primary immune thrombocytopenia: a post-hoc analysis of a multicenter, randomized phase III trialHeng Mei, Xiaofan Liu, Yan Li, et al.
Research and Practice in Thrombosis and Haemostasis|December 10, 2025
Hetrombopag for patients with persistent primary immune thrombocytopenia: a post hoc analysis of a multicenter, randomized phase Ⅲ trialHeng Mei, Xiaofan Liu, Yan Li, et al.
Circulation|May 19, 2020
Deep Vein Thrombosis in Hospitalized Patients With COVID-19 in Wuhan, China: Prevalence, Risk Factors, and OutcomeLi Zhang, Xiaokai Feng, Danqing Zhang, et al.
The Journal of Clinical Investigation|December 9, 2025
Combined FXIII-C3 autoantibodies elicit bleeding and complement dysfunction in autoimmune FXIII deficiencyShanshan Luo, Jun Deng, Yue Liu, et al.
Blood Advances|February 24, 2026
Phase 2 study of relmacabtagene autoleucel (CD19 CAR-T) for relapsed/refractory mantle cell lymphoma in Chinese adultsYan Xie, Ke-Shu Zhou, Lan-Fang Li, et al.
JAMA|June 4, 2020
Effect of Convalescent Plasma Therapy on Time to Clinical Improvement in Patients With Severe and Life-threatening COVID-19: A Randomized Clinical TrialLing Li, Wei Zhang, Yu Hu, et al.
Blood Science (Baltimore, Md.)|September 3, 2025
China Expert consensus on the application of metagenomic next-generation sequencing for the etiological diagnosis of infections in hematological disorders (2024)Chunhui Xu, Ren Lin, Ye Bai, et al.
Journal of Hematology & Oncology|February 26, 2021
A multicenter, randomized phase III trial of hetrombopag: a novel thrombopoietin receptor agonist for the treatment of immune thrombocytopeniaHeng Mei, Xiaofan Liu, Yan Li, et al.
Pageof 19